Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

-Ahead of print
-Authors' Accepted
    Manuscripts
new!
-Current Issue
-Archive
-Acknowledgments
-Special Issues
-Browse by Category

Manuscript Submission

-Online Submission
-Online Review
-Instruction for Authors
-Instruction for Reviewers
-English Corner new!

About AJA

-About AJA
-Editorial Board
-Contact Us
-News

Resources & Services

-Advertisement
-Subscription
-Email alert
-Proceedings
-Reprints

Download area

-Copyright licence
-EndNote style file
-Manuscript word template
-Guidance for AJA figures
    preparation (in English)

-Guidance for AJA figures
    preparation (in Chinese)

-Proof-reading for the
    authors

-AJA Club (in English)
-AJA Club (in Chinese)

 
中文摘要

《亚洲男性学杂志》 2012; 14 (5): 726-731

《亚洲男性学杂志》 2012; 14 (5): 726-731

前列腺癌与MDM2 T309G多态性的风险、恶性程度、临床进展:一个多态性分析

Jie Yang, Wen Gao, Ning-Hong Song, Wei Wang, Jie-Xiu Zhang, Pei Lu, Li-Xin Hua and Min Gu (中国)

为探讨MDM2基因T309G多态性与前列腺癌(PCa)发病风险、恶性程度及临床进展间的关系,我们检索PubMed后,对全部7个已发表的相关研究进行了meta分析(共含5151个PCa病例和1003个对照)。在总体分析中,我们发现309G等位基因和低PCa发病风险显著相关(OR=0.85, 95% CI: 0.74-0.97),其中纯合子比较 GG vs. TT (OR=0.72, 95% CI: 0.55-0.95),优势遗传模型比较GT+GG vs. TT (OR=0.79, 95% CI: 0.65-0.96)。同时我们也发现309G等位基因也和更低肿瘤恶性度显著相关(OR=0.85, 95% CI: 0.75-0.96),其中杂合子比较GT vs. TT (OR=0.79, 95% CI: 0.65- 0.96),纯合子比较GG vs. TT (OR=0.76, 95% CI: 0.58-0.98),优势遗传模型比较GT+GG vs. TT (OR=0.81, 95% CI: 0.68-0.96)。此外,分层分析显示309G等位基因在高加索人群中和低PCa发病风险显著相关(OR=0.77, 95% CI: 0.61-0.96),其中纯合子比较GG vs. TT (OR=0.51, 95% CI: 0.31-0.86)。通过分层分析,我们也发现在所有遗传学模型中309G等位基因在高加索人群中和PCa更低恶性度及更慢临床进展显著相关。综上所述,通过meta分析我们发现在高加索人群中MDM2基因309G等位基因和低PCa发病率、更低恶性度及更慢临床进展显著相关,但在亚洲人群中尚未发现显著相关性。

关键词:临床进展,恶性程度,MDM2,萃取分析,多态性,前列腺癌,风险

此摘要文献来源:
Jie Yang, Wen Gao, Ning-Hong Song, Wei Wang, Jie-Xiu Zhang et al. The risks, degree of malignancy and clinical progression of prostate cancer associated with the MDM2 T309G polymorphism: a meta-analysis. Asian J Androl 2012; 14: 726-31.

 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.